Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-03-27-Speech-4-014"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20030327.1.4-014"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, first of all I very much wish to congratulate Gérard Caudron on his report concerning the first application of Article 169 of the Treaty to the Sixth Framework Research and Development Programme. His work has certainly fostered excellent cooperation between us and has facilitated the success of this excellent proposal. This is due to the courageous initiative taken by Commissioner Busquin, and involves allocating a total of EUR 600 million to large-scale research with the objective of combating HIV/AIDS, malaria and tuberculosis under the EDCTP programme.
Because of the importance of that objective and the means being implemented to achieve it, it is vital for us to stress that basic ethical standards need to be respected in relation to this research. We equally need to emphasise that the results of that research should be available for use in the general interest, and that we need to cooperate with developing countries and encourage scientific and technical development in those countries. The ethical principles in question are those set out in Article 6 of the Treaty on European Union and in the Charter of Fundamental Rights, and those defined in the World Medical Association’s Helsinki Declaration on ethical principles for medical research involving human subjects. The European and Developing countries Clinical Trials Partnership must apply the good clinical practice defined in Directive 2001/20/EC on the conduct of clinical trials on medicinal products for human use in the European Union.
The EDCTP programme should encourage the training of specialists and capacity building in developing countries, step up technology transfer to those countries and mobilise additional resources for the fight against these diseases. The Community will ensure that these strategic decisions and the implementation of programmes are in line with the objective of placing on the market products that are at the same time effective, accessible at the lowest possible price and easy to use, and adapted to the specific conditions prevailing in developing countries. These decisions should be based on the active participation of stakeholders from the developing countries, scientific experts from the North and the South, representatives of patient groups, and the NGOs and the WHO.
Finally, our Group of the Greens/European Free Alliance hopes that the results obtained through this programme will be considered a public good, and will therefore not be subject to intellectual property rules such as those defined in the TRIPS agreements, so as to guarantee developing countries access to the treatments resulting from this research at the lowest possible price."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples